doi:10.1016/j.atherosclerosis.2017.06.009engBea, A.M.Perez-Calahorra, S.Marco-Benedi, V.Lamiquiz-Moneo, I.Jarauta, E.Mateo Gallego, R.Civeira, F.Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemiaART-2017-99664Background and aims: The effect of LDLc lowering with PCSK9 antibodies on tendon xanthomas (TX) is unknown. Methods: TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year. Results: Exposure to PCSK9 inhibitors in cases was 2.96 ± 1.33 years. LDLc decreased 80.8 ± 7.66% in cases and 56.9 ± 11.1% in controls. There was a decrease in maximum (-5.03%) and mean (-5.32%) TX in cases but not in controls (+3.97%, +3.16, respectively, p = 0.01). PCSK9 inhibitor treatment was independently associated with TX reduction. Conclusion: Addition of a PCSK9 inhibitor to statin and ezetimibe resulted in a greater decrease in LDLc and TX after 3 years of treatment.2017http://zaguan.unizar.es/record/13028410.1016/j.atherosclerosis.2017.06.009http://zaguan.unizar.es/record/130284oai:zaguan.unizar.es:130284info:eu-repo/grantAgreement/ES/ISCIII/FIS/IIS16-0114info:eu-repo/grantAgreement/ES/ISCIII/FIS/PIE16-00022info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01983Atherosclerosis 263 (2017), 92-96by-nc-ndhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccess